Neuberger Berman High Yield Strategies Fund Inc.
Share Price & News
How has Neuberger Berman High Yield Strategies Fund's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NHS's share price has been volatile over the past 3 months.
7 Day Return
US Capital Markets
1 Year Return
US Capital Markets
Return vs Industry: NHS underperformed the US Capital Markets industry which returned -14.5% over the past year.
Return vs Market: NHS underperformed the US Market which returned -15.9% over the past year.
Price Volatility Vs. Market
How volatile is Neuberger Berman High Yield Strategies Fund's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Neuberger Berman High Yield Strategies Fund undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NHS ($8.3) is trading below our estimate of fair value ($12.6)
Significantly Below Fair Value: NHS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NHS is good value based on its PE Ratio (7.2x) compared to the Capital Markets industry average (33.7x).
PE vs Market: NHS is good value based on its PE Ratio (7.2x) compared to the US market (12.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NHS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NHS is good value based on its PB Ratio (0.7x) compared to the US Capital Markets industry average (7.7x).
How is Neuberger Berman High Yield Strategies Fund forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Diversified Financials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neuberger Berman High Yield Strategies Fund has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Neuberger Berman High Yield Strategies Fund performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NHS has a large one-off gain of $8.6M impacting its October 31 2019 financial results.
Growing Profit Margin: NHS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: NHS's earnings have grown by 18.2% per year over the past 5 years.
Accelerating Growth: NHS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NHS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (9.7%).
Return on Equity
High ROE: NHS's Return on Equity (9.1%) is considered low.
How is Neuberger Berman High Yield Strategies Fund's financial position? (This company is analysed differently as a bank or financial institution)
Financial Position Analysis
Debt to Equity History and Analysis
Inventory Level: NHS has a low level of unsold assets or inventory.
Debt Coverage by Assets: NHS's debt is not covered by short term assets (assets are 0.1x debt).
Financial Institutions Analysis
Asset Level: NHS's level of assets compared to its equity is low.
Allowance for Bad Loans: Insufficient data to determine if NHS has a sufficient allowance for bad loans.
Low Risk Liabilities: NHS reports no customer deposits, loans are made up entirely of externally borrowed funds.
Loan Level: Insufficient data to determine if NHS has an acceptable proportion of non-loan assets held.
Low Risk Deposits: NHS has advanced significantly more loans than the customer deposits it holds.
Level of Bad Loans: Insufficient data to determine if NHS has an appropriate level of bad loans.
What is Neuberger Berman High Yield Strategies Fund's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: NHS's dividend (13.08%) is higher than the bottom 25% of dividend payers in the US market (2.07%).
High Dividend: NHS's dividend (13.08%) is in the top 25% of dividend payers in the US market (5.82%)
Stability and Growth of Payments
Stable Dividend: NHS's dividends per share have been stable in the past 10 years.
Growing Dividend: NHS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (81.4%), NHS's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Robert Conti (63yo)
Mr. Robert John Conti, also known as Bobby, has been the Chief Executive Officer and President of Neuberger Berman BD LLC since 2008. Mr. Conti has been a Managing Director at Neuberger Berman LLC since 20 ...
|Chief Executive Officer||no data||no data||no data|
|Director||11.25yrs||no data||no data|
|Independent Director||14yrs||US$16.86k||no data|
|Independent Director||12.83yrs||US$16.42k||no data|
|Non-Executive Chairman||11.33yrs||US$20.54k||no data|
|Independent Director||14yrs||US$17.58k||no data|
|Independent Director||14yrs||US$18.02k||no data|
|Independent Director||14yrs||US$17.58k||no data|
|Independent Director||13.25yrs||US$17.58k||0.020% $31.7k|
|Independent Director||13.25yrs||US$17.58k||no data|
Experienced Board: NHS's board of directors are seasoned and experienced ( 13.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neuberger Berman High Yield Strategies Fund Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Neuberger Berman High Yield Strategies Fund Inc.
- Ticker: NHS
- Exchange: AMEX
- Founded: 2003
- Industry: Asset Management and Custody Banks
- Sector: Diversified Financials
- Market Cap: US$162.187m
- Shares outstanding: 19.54m
- Website: https://www.nb.com/Pages/Public/en-us/Products/high-yield-strategies-fund.aspx
- Neuberger Berman High Yield Strategies Fund Inc.
- 1290 Avenue of the Americas
- New York City
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NHS||AMEX (NYSE MKT LLC)||Yes||Common Shares||US||USD||Jul 2003|
Neuberger Berman High Yield Strategies Fund Inc. is a closed-ended fixed income mutual fund launched by Neuberger Berman LLC. The fund is managed by Neuberger Berman Investment Advisers LLC. It invests in fixed income markets across the globe. The fund typically invests in high yield debt securities of various sectors, such as auto parts and equipment, airlines, automotive, electronics, health services, packaging, telecom-integrated/services, gaming, and gas distribution. It was formerly known as Neuberger Berman High Yield Strategies Fund. Neuberger Berman High Yield Strategies Fund Inc. was formed on July 28, 2003 and is domiciled in the United States.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 05:14|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.